BETHESDA, Md., May 21, 2015 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a
biotechnology company developing DCVax® personalized immune
therapies for cancer, announced today that Dr. Marnix L. Bosch, Chief Technical Officer of the
Company, will be making a presentation at the New York Academy of
Sciences' Conference on Emerging Approaches to Immunotherapy at
11:40 a.m. on May 21, 2015, at
the Academy in New York City.
Dr. Bosch's presentation is entitled "DCVax-Direct, A New
Dendritic Cell Therapy For Cancer." During his presentation, Dr.
Bosch will discuss the scientific basis for the DCVax-Direct
technology, and emerging observations from the Phase I/II clinical
trial for inoperable solid tumor cancers.
The conference is not being webcast. Dr. Bosch's
presentation slides will be made available after the conference
sessions on the Company's website at www.nwbio.com
Dr. Bosch will also be presenting further observations
concerning DCVax-Direct at another forum within the next several
weeks.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both
the United States and
Europe. The Company has a broad platform technology for DCVax
dendritic cell-based vaccines. The Company's lead program is
a 348-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal form
of brain cancer, and is an "orphan disease." The Company is
under way with a 60-patient Phase I/II trial with DCVax-Direct for
all types of inoperable solid tumor cancers. It has completed
enrollment in the Phase I portion of the trial, and is in
preparation for two Phase II trials. The Company previously
received clearance from the FDA for a 612-patient Phase III trial
in prostate cancer. The Company conducted a Phase I/II trial
with DCVax for metastatic ovarian cancer together with the
University of Pennsylvania. In Germany, the Company has also received
approval of a 5-year Hospital Exemption for the treatment of all
gliomas in patients outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's ongoing
ability to raise additional capital, risks related to the Company's
ability to enroll patients in its clinical trials and complete the
trials on a timely basis, uncertainties about the clinical trials
process, uncertainties about the timely performance of third
parties, risks related to whether the Company's products will
demonstrate safety and efficacy, risks related to the Company's and
Cognate's abilities to carry out the intended manufacturing
expansions contemplated in the Cognate Agreements, risks related to
the Company's ability to carry out the Hospital Exemption program
and risks related to possible reimbursement and pricing.
Additional information on these and other factors, including Risk
Factors, which could affect the Company's results, is included in
its Securities and Exchange Commission ("SEC") filings.
Finally, there may be other factors not mentioned above or included
in the Company's SEC filings that may cause actual results to
differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation
to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nw-bio-to-present-at-new-york-academy-of-sciences-conference-on-emerging-approaches-to-immunotherapy-300087277.html
SOURCE Northwest Biotherapeutics, Inc.